key: cord-0817357-yztuby2v
authors: Yang, Jee Myung; Koh, Hyun Yong; Moon, Sung Yong; Yoo, In Kyung; Ha, Eun Kyo; You, Seulgi; Kim, So Young; Yon, Dong Keon; Lee, Seung Won
title: Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study
date: 2020-08-15
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2020.08.008
sha: cd623695296376d82ce83fd9ab3fd26fe65bbc07
doc_id: 817357
cord_uid: yztuby2v

Abstract Background There is inconclusive and controversial evidence of the association between allergic diseases and the risk of adverse clinical outcomes of the coronavirus disease (COVID-19). Objective To determine the association of allergic disorders with the likelihood of a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result and with clinical outcomes of COVID-19 (admission to intensive care unit, administration of invasive ventilation, and death). Methods A propensity-score-matched nationwide cohort study was performed in South Korea. Data obtained from the Health Insurance Review & Assessment Service of Korea from all adult patients (age >20 years) who were tested for SARS-CoV-2 in South Korea between January 1, 2020 and May 15, 2020 were analyzed. The association of SARS-CoV-2 test positivity and allergic diseases in the entire cohort (n=219,959) and the difference of clinical outcomes of COVID-19 were evaluated in patients with allergic diseases and SARS-CoV-2 positivity (n=7340). Results In the entire cohort, patients who underwent SARS-CoV-2 testing were evaluated to ascertain whether asthma and allergic rhinitis were associated with an increased likelihood of SARS-CoV-2 test positivity. After propensity score matching, we found that asthma and allergic rhinitis were associated with worse clinical outcomes of COVID-19 in patients with SARS-CoV-2 positivity. Patients with non-allergic asthma had a greater risk of SARS-CoV-2 test positivity and worse clinical outcomes of COVID-19 than patients with allergic asthma. Conclusion In a Korean nationwide cohort, allergic rhinitis and asthma, especially non-allergic asthma, confers a greater risk of susceptibility to SARS-CoV-2 infection and severe clinical outcomes of COVID-19.

Data were obtained from a Korean national health insurance claims-based database. The provided mandatory and free health insurance for all 24 156 Therefore, the data set analyzed in this study includes the records of personal data, healthcare additional propensity score matching sets based on the current allergic status.

Each matching was undertaken in a 1:1 ratio using a "greedy nearest-neighbor" algorithm 218 among all individuals who underwent SARS-CoV-2 testing and among patients who tested 219 positive for SARS-CoV-2 infection. 32 We used a logistic regression model adjusted for age; 220 sex; region of residence; history of diabetes mellitus, cardiovascular disease, cerebrovascular 221 disease, COPD, hypertension, or chronic kidney disease; the Charlson Comorbidity Index; 222 and use of immunosuppressants. The adequacy of matching was confirmed by comparing 223 propensity score densities (Figures S1-S12) and standardized mean differences (SMD). 26 224 Data were analyzed by using binary logistic regression or analysis of covariance 225 (ANCOVA) models. The estimation of the adjusted odds ratios (aORs) with 95% confidence 226 intervals (CIs) or the adjusted mean difference (with 95% CIs) was performed after adjusting 227 for the following potential confounders to reduce the possibility of bias: age; sex; region of 228 residence (urban or rural); history of diabetes mellitus, cardiovascular disease, 229 cerebrovascular disease, COPD, hypertension, and chronic kidney disease; the Charlson 230 Comorbidity Index (0, 1, and ≥2); previous use of systemic glucocorticoids and 231 immunosuppressants; and allergic disorders (as relevant). Statistical analyses were performed 232 in SAS version 9.4 (SAS Institute Inc.). A two-sided P value of less than 0.05 was considered 233 statistically significant. 235 A primary analysis (a positive laboratory test results for COVID-19) using binary logistic 236 regression, a secondary analysis (a severe clinical outcomes of COVID-19) using binary 237 logistic regression, and another secondary analysis (length of hospital stay) using ANCOVA 2) we redefined the cohort by using a stricter definition of "current allergic status".

Patient and public involvement 243 No patients were directly involved in designing the research question or in conducting the 244 research. No patients were asked for advice on interpretation or writing up of the results.

There are no plans to involve patients or the relevant patient community in the dissemination 246 of study findings at this time.

J o u r n a l P r e -p r o o f 249 The demographics and clinical characteristics of a total of 219,959 patients ( 258 After propensity score matching among patients who were tested for SARS-CoV-2 (n = 259 219,959), there were no major imbalances in the baseline covariates evaluated by SMD 260 between both groups (Table II; all SMDs < 0.1). Table II Figure III) . Analyses 266 using a stricter definition of current allergic diseases also showed a significantly increased 267 risk of SARS-CoV-2 test positivity (Table S1 ). Analysis of the effect of atopic status 268 indicated that individuals with non-allergic asthma had a greater risk of SARS-CoV-2 test 269 positivity (aOR, 1.34; 95% CI, 1.07-1.71) than those with allergic asthma (aOR, 1.06; 95% 270 CI, 0.97-1.17) ( Table IV) .

J o u r n a l P r e -p r o o f

After propensity score matching among patients who tested positive for SARS-CoV-2 (n = 273 7340), there were no major imbalances in the baseline covariates evaluated by SMD between 274 both groups (Table III; all SMDs <0.1, except for a history of cerebrovascular disease and 275 hypertension among patients without atopic dermatitis versus those with atopic dermatitis). 276 Table III describes the ORs for the association of severe clinical outcomes of COVID-19 with 277 allergic diseases among patients who tested positive for SARS-CoV-2; among these patients, 278 the rates of severe clinical outcomes of COVID-19 were 6.9% and 4.5% in patients with and 279 without asthma, respectively (aOR, 1.62; 95% CI, 1.01-2.67) and 4.7% and 3.7% in patients 280 with and without allergic rhinitis, respectively (aOR, 1.27; 95% CI, 1.00-1.64, P value 281 <0.05) (Table III and Figure III) . Furthermore, analyses using a stricter definition of current 282 allergic diseases showed a significantly increased risk of severe outcomes of COVID-19 283 ( Table S2 ). The analysis of the effect of atopic status indicated that individuals with non-284 allergic asthma had a greater risk for severe outcomes of COVID-19 (aOR, 4.09; 95% CI, 285 1.69-10.52) than those with allergic asthma (aOR, 1.40; 95% CI, 0.83-2.41) (Table IV) .

To gain additional insights into the association between allergic diseases and the clinical 287 outcomes of COVID-19, we conducted an analysis of the length of hospital stay (Table III) . A SMD of less than 0.1 indicates no major imbalance. All SMD values were less than 0.1 in each propensity-score-matched cohort Numbers in bold indicate significant differences (P < 0.05).

J o u r n a l P r e -p r o o f A SMD of less than 0.1 indicates no major imbalance. All SMD values were less than 0.1 in each propensity-score-matched cohort, except history of cerebrovascular disease and hypertension among patients without atopic dermatitis versus those with atopic dermatitis. 

Demographic and clinical characteristics of all patients tested for severe acute respiratory syndrome 2 (SARS-CoV-2

History of hypertension, n (%) 66,281 (30.1) 64,643 (30.4)

Exposure Previous use of systemic glucocorticoids, n (%) 80,943 (36.8)

Abbreviations: COPD, chronic obstructive pulmonary disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SMD, standardized mean difference

Abbreviations: CI, confidence interval

chronic obstructive pulmonary disease; COVID-19, coronavirus disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; OR, odds ratio

* Minimally adjusted: adjustment for age and sex

§ Fully adjusted: adjustment for the age, sex, region of residence, history of diabetes mellitus, cardiovascular disease, cerebrovascular disease, COPD, hypertension, chronic kidney disease, Charlson Comorbidity Index, use of immunosuppressants, use of systemic glucocorticoids, allergic rhinitis

‡ Fully adjusted: adjustment for the age, sex, region of residence, history of diabetes mellitus, cardiovascular disease, cerebrovascular disease, COPD, hypertension, chronic kidney disease, Charlson Comorbidity Index, use of immunosuppressants, use of systemic glucocorticoids, asthma, and atopic dermatitis

adjusted: adjustment for the age, sex, region of residence, history of diabetes mellitus, cardiovascular disease, cerebrovascular disease, COPD, hypertension, chronic kidney disease, Charlson Comorbidity Index, use of immunosuppressants, use of systemic glucocorticoids, asthma, and allergic rhinitis

A SMD of less than 0.1 indicates no major imbalance. All SMD values were less than 0.1 in each propensity-score-matched cohort . Numbers in bold indicate significant differences

Propensity-score-matched subgroup analyses for the association of SARS-CoV-2 test positivity with asthma phenotypes among all patients who underwent SARS-CoV-2 testing and clinical outcomes or length of hospital stay with asthma phenotypes among patients with laboratory-confirmed SARS-CoV-2 infection. Exposure Event Event number/total number (%) Fully adjusted OR * (95% CI) , day (SD)

Abbreviations: CI, confidence interval

chronic obstructive pulmonary disease; COVID-19, coronavirus disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

* Fully adjusted: adjustment for the age, sex, region of residence, history of diabetes mellitus, cardiovascular disease, cerebrovascular disease, COPD, hypertension